Cytokinetics(US:CYTK) Newsfilter·2024-05-15 11:30Core Insights - Cytokinetics announced five presentations related to aficamten at the European Society of Cardiology Congress 2024, scheduled for August 30 to September 2, 2024 in London, UK [1] Group 1: Presentations on Aficamten - The first presentation titled "Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy" will be presented by Dr. Ahmad Masri on August 30, 2024 [2] - A second presentation on "Clinical Application of Biomarkers in Obstructive Hypertrophic Cardiomyopathy: Insights from SEQUOIA-HCM" will be delivered by Dr. Caroline Coats on September 1, 2024 [2] - Dr. Ahmad Masri will also present an integrated safety analysis of aficamten in patients with obstructive hypertrophic cardiomyopathy on September 1, 2024 [2] - Dr. Sheila Hegde will discuss the impact of aficamten on echocardiographic cardiac structure and function in adults with symptomatic obstructive hypertrophic cardiomyopathy on September 2, 2024 [2] - The final presentation titled "Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM" will be presented by Dr. John A. Spertus on September 2, 2024 [2] Group 2: Company Overview - Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on developing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases with compromised cardiac muscle performance [3] - The company is preparing for regulatory submissions for aficamten following positive results from the SEQUOIA-HCM Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy [3] - Aficamten is also being evaluated in multiple Phase 3 clinical trials, including MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM [3] - Additionally, Cytokinetics is developing other drug candidates such as omecamtiv mecarbil for heart failure and CK-586 and CK-136 for various types of heart failure [3]